EP 1163208 A2 20011219 - CASPASE INHIBITORS AND USES THEREOF
Title (en)
CASPASE INHIBITORS AND USES THEREOF
Title (de)
CASPASE INHIBITOREN UND DEREN VERWENDUNG
Title (fr)
INHIBITEURS DE CASPASE ET LEURS UTIILSATIONS
Publication
Application
Priority
- US 0021503 W 20000804
- US 14770699 P 19990806
Abstract (en)
[origin: WO0110383A2] This invention provides novel compounds that are effective as inhibitors of caspase and cellular apoptosis. The invention also provides methods for using the compounds to treat caspase-mediated diseases in mammals. The compounds have the general formula (I): wherein X is F or C1; R<1> is COOH, COO(alkyl), or an isostere thereof; and R<2> is an aryl group.
IPC 1-7
IPC 8 full level
A61K 31/197 (2006.01); A61K 31/275 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/40 (2006.01); A61K 31/404 (2006.01); A61K 31/426 (2006.01); A61K 31/4409 (2006.01); A61K 31/455 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 1/18 (2006.01); A61P 3/10 (2006.01); A61P 5/16 (2006.01); A61P 7/04 (2006.01); A61P 7/06 (2006.01); A61P 9/04 (2006.01); A61P 9/10 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 17/02 (2006.01); A61P 17/06 (2006.01); A61P 17/14 (2006.01); A61P 21/00 (2006.01); A61P 21/02 (2006.01); A61P 21/04 (2006.01); A61P 25/00 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); A61P 31/00 (2006.01); A61P 31/06 (2006.01); A61P 31/12 (2006.01); A61P 31/18 (2006.01); A61P 31/20 (2006.01); A61P 33/02 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/00 (2006.01); A61P 37/06 (2006.01); A61P 43/00 (2006.01); C07C 231/12 (2006.01); C07C 233/83 (2006.01); C07C 235/52 (2006.01); C07C 237/36 (2006.01); C07C 253/30 (2006.01); C07C 255/57 (2006.01); C07C 255/60 (2006.01); C07D 207/34 (2006.01); C07D 207/416 (2006.01); C07D 209/42 (2006.01); C07D 213/81 (2006.01); C07D 213/82 (2006.01); C07D 277/20 (2006.01); C07D 277/56 (2006.01); C07D 307/68 (2006.01); C07D 333/38 (2006.01); C07D 333/40 (2006.01)
CPC (source: EP US)
A61P 1/04 (2017.12 - EP); A61P 1/16 (2017.12 - EP); A61P 1/18 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 5/16 (2017.12 - EP); A61P 7/04 (2017.12 - EP); A61P 7/06 (2017.12 - EP); A61P 9/04 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/02 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 17/14 (2017.12 - EP); A61P 21/00 (2017.12 - EP); A61P 21/02 (2017.12 - EP); A61P 21/04 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/14 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/00 (2017.12 - EP); A61P 31/06 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 31/20 (2017.12 - EP); A61P 33/02 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07C 233/83 (2013.01 - EP US); C07C 235/52 (2013.01 - EP US); C07C 237/36 (2013.01 - EP US); C07C 255/57 (2013.01 - EP US); C07D 207/34 (2013.01 - EP US); C07D 209/42 (2013.01 - EP US); C07D 213/81 (2013.01 - EP US); C07D 213/82 (2013.01 - EP US); C07D 277/56 (2013.01 - EP US); C07D 307/68 (2013.01 - EP US); C07D 333/38 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0110383 A2 20010215; WO 0110383 A3 20010907; AT E266623 T1 20040515; AU 6894800 A 20010305; DE 60010675 D1 20040617; DE 60010675 T2 20050616; DK 1163208 T3 20040816; EP 1163208 A2 20011219; EP 1163208 A4 20020703; EP 1163208 B1 20040512; ES 2219381 T3 20041201; JP 2003506389 A 20030218; PT 1163208 E 20040831; TW I281910 B 20070601; US 2002132833 A1 20020919; US 6632962 B2 20031014
DOCDB simple family (application)
US 0021503 W 20000804; AT 00957311 T 20000804; AU 6894800 A 20000804; DE 60010675 T 20000804; DK 00957311 T 20000804; EP 00957311 A 20000804; ES 00957311 T 20000804; JP 2001514908 A 20000804; PT 00957311 T 20000804; TW 89115790 A 20000805; US 83405201 A 20010403